Literature DB >> 7551570

NGF binding to the trk tyrosine kinase receptor requires the extracellular immunoglobulin-like domains.

P Pérez1, P M Coll, B L Hempstead, D Martín-Zanca, M V Chao.   

Abstract

Neurotrophins initiate their biological effects by activating members of the trk tyrosine kinase subfamily. The extracellular region of trk receptors is distinguished by several common structural features, including leucine-rich repeats, clusters of cysteine-rich domains, and two immunoglobulin-like domains. However, the receptor sequences required for ligand binding have not been localized. In order to define the domains involved in NGF binding, a series of chimeric receptors was constructed using cDNA sequences from rat trkA and trkB. The chimeric constructs were expressed after transient transfection in 293 cells and the expression of each receptor was verified by immunoprecipitation and immunoblot analysis. Equilibrium binding of transfected cells revealed that the two IgG domains of trkA are essential for NGF binding. The requirement for the two IgG domains was further confirmed by Scatchard analysis and affinity crosslinking with 125I-NGF. These results indicate that NGF binding is crucially dependent upon interactions with the IgG domains of the trkA receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7551570     DOI: 10.1006/mcne.1995.1010

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  22 in total

1.  TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor.

Authors:  J C Arevalo; B Conde; B L Hempstead; M V Chao; D Martin-Zanca; P Perez
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

Review 2.  Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury.

Authors:  J Gordon Boyd; Tessa Gordon
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

3.  Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor.

Authors:  M Cazorla; J M Arrang; J Prémont
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 4.  Cardiovascular actions of neurotrophins.

Authors:  Andrea Caporali; Costanza Emanueli
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

5.  Characterization of the recombinant extracellular domain of the neurotrophin receptor TrkA and its interaction with nerve growth factor (NGF).

Authors:  S B Woo; C Whalen; K E Neet
Journal:  Protein Sci       Date:  1998-04       Impact factor: 6.725

6.  Optimal nerve growth factor trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands.

Authors:  S Maliartchouk; H U Saragovi
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

7.  The N-terminal globular domain of Eph receptors is sufficient for ligand binding and receptor signaling.

Authors:  J P Labrador; R Brambilla; R Klein
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

8.  Early evolutionary origin of the neurotrophin receptor family.

Authors:  R E van Kesteren; M Fainzilber; G Hauser; J van Minnen; E Vreugdenhil; A B Smit; C F Ibáñez; W P Geraerts; A G Bulloch
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

9.  Molecular cloning of a novel membrane glycoprotein, pal, specifically expressed in photoreceptor cells of the retina and containing leucine-rich repeat.

Authors:  F Gomi; K Imaizumi; T Yoneda; M Taniguchi; Y Mori; K Miyoshi; J Hitomi; T Fujikado; Y Tano; M Tohyama
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

10.  Time course and nerve growth factor dependence of inflammation-induced alterations in electrophysiological membrane properties in nociceptive primary afferent neurons.

Authors:  L Djouhri; D Dawbarn; A Robertson; R Newton; S N Lawson
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.